Epigenetic targets as an approach to cancer therapy and chemoprevention

Drugs of the Future

Volumn 31, Issue 4, 2006, Pages 335-344

  Sorbera, Lisa A ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; BEVACIZUMAB; BUTYRIC ACID; CHAP 1; CRA 026440; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; ERLOTINIB; FLUOROURACIL; HDAC 42; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LBH 589 1; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PYROXAMIDE; RG 108; ROMIDEPSIN; SB 623; SB 624; SB 639; SK 7041; TRAPOXIN B; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; WO 2003066579; WO 2004092115; WO 2005019174; WO 2005097770;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CELL POPULATION; CELL PROLIFERATION; CLINICAL TRIAL; DEACETYLATION; DNA METHYLATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EPIGENETICS; FATIGUE; HISTIOCYTIC LYMPHOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MEDICAL SOCIETY; MONOTHERAPY; NAUSEA AND VOMITING; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE;

EID: 33745208735     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.04.985053     Document Type: Review

References (52)

1. Yoo, C.B., Jones, P.A. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 2006, 5: 37-50.
2. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16: 6-21.
3. Laird, P.W. Cancer epigenetics. Hum Mol Genet 2005, 14(1): R65-76.
4. Johnstone, R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1: 287-99.
5. Egger, G., Ling, G., Aparicio, A., Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429: 457-63.
6. Esteller, M. DNA methylaton and cancer therapy: New developments and expectations. Curr Opin Oncol 2005, 17: 55-60.
7. Hashimshony, T., Zhang, J., Keshet, I., Bustin, M., Cedar, H. The role of DNA methylation in setting up chromatin structure during development. Nat Genet 2003, 34: 187-92.
8. Kaminskas, E. et al. Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005, 11: 3604-8.
9. Pauer, L.R. et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 2004, 22: 886-96.
10. Curt, G.A. et al. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). Cancer Res 1985, 45: 3359-63.
11. Zambrano P. et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005, 5: 44.
12. Davis, A. et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003, 21: 85-97.
13. Raffoux, E., Chaibi, P., Dombret, H., Degos, L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005, 90: 986-8.
14. Monneret, C. Histone deacetylase inhibitors. Eur J Med Chem 2005, 40: 1-13.
15. Kelly, W.K. et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9: 3578-88.
16. Gibbons, R.J. Histone modifying and chromatin remodeling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005, 14(1): R85-92.
17. Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 2005, 13: 1139-44.
18. Qiu, L. et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000, 11: 2069-83.
19. Giles, F.J. et al. A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies. Blood 2004, 104: 499A.
20. Sandor, V. et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002, 8: 718-28.
21. Camphausen, K. et al. Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004, 64: 316-21.
22. Nishino, N. et al. Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. Org Lett 2003, 5: 5079-82
23. Fournel, M., Moradei, O., Paquin, I. et al. Enhanced isotype-selectivity and antiproliferative activity of thiophenyl derivatives of benzamide HDAC inhibitors in human cancer cells. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 4725.
24. Entzeroth, M.B., Sangthongpitag, K., Goh, S.K. et al. Potent antitumour activity of N-hydroxy-3-benzimidazole-5-yl acrylamides. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 3811.
25. Cao, Z.A., Bass, K.E., Balasubramanian, S. et al. The effects of histone deacetylase (HDAC) inhibitor, CRA-026440, on angiogenesis, signal transduction and tumor growth. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 5047.
26. Mand, M., Edwards, C., Tumati, V. et al. A novel histone deacetylase inhibitor with potent antiproliferative activity in ovarian cancer cells. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 5039.
27. Mortazavi, A., Hoot, D.R., Carlton, P.S., Chen, C.-S., Clinton, S.K. Modulation of ErbB family receptors by a novel histone deacetylase inhibitor HDAC-42, in bladder cancer cell lines. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 5044.
28. Beyer, S.J., Kulp, S.K., Baird, M. et al. The effects of a phenylbutyrate-derived histone deacetylase inhibitor (HDAC-42) on acid-induced gene expression patterns of SEG-1 human esophageal adenocarcinoma cells. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 4807.
29. Gupta, S., Girdhni, S., Boyer, S.J., Chen, C.-S., Ahmed, M.M. Novel histone deacetylase inhibitors as radiosensitizers in the treatment of prostate cancer. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 5310.
30. Kim, I.-A., Shin, J.-H., Kim, I.-H. et al. HDAC inhibitor-mediated radiosensitization of human cancer cells: Class differences and the potential influence of p53. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 5038.
31. Qian, X., LaRochelle, W.J., Ara, G., Sehested, M., Lichestein, H.S., Jeffers, M. Activity of the HDAC inhibitor. PXD101. used as monotherapy and combination therapy in preclinical NSCLC studies. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 4743.
32. Lillehammer, T., Maelandsmo, G.M., Fodstad, O., Engebraaten, O. Combined treatment with Ad-TRAIL and chemotherapy (DTIC and SAHA) in human melanoma cell lines. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 5481.
33. Rubin, E.H., Mazina, K.E., Agrawal, N. et al. A phase I study evaluating the safety, tolerability, and pharmacokinetics of oral vonnostat (VOR) in patients with advanced cancer. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 2907.
34. Kato, Y., Yoshimura, K., Shin, T. et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 5053.
35. Zhou, Q., Agoston, A.T., Blum, J., Atadja, P., Nelson, W.G., Davidson, N.E. Histone deacetylase inhibition reactivates the silenced estrogen receptor alpha gene and sensitizes ER-negative human breast cancer cells to tamoxifen. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 2280.
36. Verheul, H.M.W., Qian, D.Z., Van Erp, K., Salumbides, B., Sanni, T., Atadja, P., Pili, R. Combination therapy targeting hypoxia inducible factor-α (HIF-1α) and tissue factor (TF) by the mTOR inhibitor rapamycin and the histone deacetylase inhibitor LBH589. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 1033.
37. Yu, C., Friday, B.B., Atadja, P., Adjei, A.A. The multi-kinase receptor inhibitor AEE-788 interacts synergistically with histone deacetylase (HDAC) inhibitors to induce apoptosis in human malignant cells. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 3783.
38. Prince, H.M., Ellis, L., Johnstone, R. et al. Oral LBH589, a novel histone deacetylase inhibitor, treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 1146.
39. Felsenfeld, G., Groudine, M. Controlling the double helix. Nature 2003, 421: 448-53.
40. Jaenisch, R., Bird, A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003, 33: 245-54.
41. Hanash, S. Integrated global profiling of cancer. Nat Rev Cancer 2004, 4: 638-44.
42. Brueckner, B. et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005, 65: 6305-11.
43. Yoo, C.B., Liang, G., Laird, P.W., Thykjaer, T., Orntoft, T.F., Marquez, V.E., Jones, P.A. The effects of long-term administration of zebularine, a DNA methylation inhibitor, in vivo. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 9.
44. Johnson, W.D., Harder, J.B., Naylor, J., McCormick, D.L., Detrisac, C.J., Glaze, E.R., Tomaszewski, J.E. A pharmacokinetic/pharmacodynamic approach to evaluating the safety of zebularine in non-human primates. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 1311.
45. Lyon, C.M., Linge, D.K., Liechty, K.C., Belinsky, S.A. DNA demethylating agents and a PPAR-γ agonist cooperate to induce apoptosis in lung cancer cell lines. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 41.
46. Gopisetty, G., Ramachandran, K., Singal, R. Upregulation of GDD45α expression either by treatment with 5′aza-2′deoxycytidine or by downregulation of MeCP2 protein increases sensitivity of Du145 cells to docetaxel chemotherapy. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 2465.
47. Teixeira, V.R., Da Costa, M., Costa, F.F., Camargo, A.A., Chammas, R. Galectin-3 gene is silenced by methylation along melanoma progression. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 1602.
48. Sankpal, U.T., Robertson, K. The mechanism of 5-aza- 2′deoxycytidine-mediated cytotoxicity in the treatment of cancer. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 2285.
49. Liu, Y., Lubet, R.A., Steele, V.E., Kramer, P.M., Nines, R., Csato, B., Pereira, M.A. Prevention by 5-aza-deoxycytidine and SAHA of vinyl carabamate-induced mouse lung tumors. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 698.
50. Cantor, J.P., Iliopoulos, D., Rao, A.S. et al. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer reduces tumorigenicity. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 2161.
51. Lakshman, T.V., Cantor, J.P., Rao, A.S., Collins, J.E., Friedberg, J.S. Effects of DNA methyltransferase and histone deacetylase inhibitors on tumorigenicity and MHC1 expression in a murine non-small cell lung cancer cell line. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 1612.
52. Cip/WAF genes in patients with MDS treated with decitabine. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 2284.